Trial Profile

A retrospective chart review study of trastuzumab deruxtecan treatment for HER2-positive breast cancer with brain metastases

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab-deruxtecan (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms ROSET-BM
Sponsors Daiichi Sankyo Inc

Most Recent Events

21 Nov 2022 According to a Daiichi Sankyo Company media release, data from the trial will be presented at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).
15 Jul 2022 Planned End Date changed from 31 Jan 2022 to 31 Jan 2023.
15 Feb 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com